Free Trial
NASDAQ:GANX

Gain Therapeutics Q3 2023 Earnings Report

Gain Therapeutics logo
$1.79 -0.10 (-5.29%)
Closing price 04:00 PM Eastern
Extended Trading
$1.82 +0.03 (+1.96%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gain Therapeutics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Gain Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gain Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Gain Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Gain Therapeutics Earnings Headlines

Why July 22nd Could Mean Big Changes for Social Security
In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22. What's coming next isn't about trimming waste.
Gain Therapeutics (GANX) Gets a Buy from Scotiabank
See More Gain Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email.

About Gain Therapeutics

Gain Therapeutics (NASDAQ:GANX), a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

View Gain Therapeutics Profile

More Earnings Resources from MarketBeat